Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reissued by equities researchers at Canaccord Genuity in a report released on Tuesday. They currently have a $16.00 price target on the specialty pharmaceutical company’s stock. Canaccord Genuity’s price target points to a potential upside of 11.42% from the company’s previous close.

VRX has been the subject of several other reports. Piper Jaffray Companies set a $14.00 price target on Valeant Pharmaceuticals International and gave the company a “sell” rating in a research report on Wednesday, August 9th. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Wednesday, August 9th. Wells Fargo & Company reiterated an “underperform” rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a research note on Saturday. Cantor Fitzgerald reissued a “buy” rating and set a $23.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday, September 28th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $18.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th. Five equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $17.67.

Valeant Pharmaceuticals International (VRX) traded down 1.78% during midday trading on Tuesday, hitting $14.36. 10,833,531 shares of the company traded hands. The stock’s 50-day moving average is $13.97 and its 200-day moving average is $13.35. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $24.89. The firm’s market capitalization is $5.00 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. During the same period in the previous year, the business earned ($0.88) EPS. The company’s revenue was down 7.7% compared to the same quarter last year. Analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/03/valeant-pharmaceuticals-international-inc-vrx-earns-hold-rating-from-canaccord-genuity.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.87% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals International in the first quarter valued at $104,000. Harbor Advisors LLC acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $110,000. PNC Financial Services Group Inc. raised its holdings in shares of Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the period. Baird Financial Group Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $127,000. Finally, OLD Mutual Customised Solutions Proprietary Ltd. raised its holdings in shares of Valeant Pharmaceuticals International by 357.7% during the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 9,300 shares during the period. 50.48% of the stock is currently owned by institutional investors and hedge funds.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.